Which Are the Emerging Companies in the Urology Devices Industry in 2025?

Introduction

The Urology devices industry is entering a transformative phase in 2025, fueled by innovation in minimally invasive therapies, smart implants, and digital health integration. While established medtech giants maintain strong market positions, several emerging and mid-tier companies are making notable progress with next-generation devices that address benign prostatic hyperplasia (BPH), urinary incontinence, and urologic cancers. These innovators are shaping the future of urological care by improving patient outcomes, reducing invasiveness, and creating more cost-effective treatment pathways.

Key Emerging & Established Players in Urology Devices Industry

Zenflow

Zenflow is redefining treatment for benign prostatic hyperplasia (BPH) with its Spring® System, a minimally invasive implant designed to restore urine flow while preserving sexual function. Backed by durable three-year clinical data and recent strategic investment from Cook Medical, Zenflow has emerged as a leader in office-based, first-line interventional therapies for men with BPH.

Promaxo

Promaxo specializes in portable, office-based MRI systems coupled with robotics for prostate interventions. Its FDA-cleared MRI platform enables targeted prostate biopsies in outpatient settings, reducing reliance on large, hospital-based imaging. By combining imaging precision with convenience, Promaxo is positioning itself as a disruptive force in prostate cancer diagnostics and treatment planning.

Neuspera Medical

Neuspera is advancing next-generation sacral neuromodulation (SNM) therapies for urinary urge incontinence. Its miniaturized, battery-free system recently achieved FDA approval, offering a wireless alternative to bulky, battery-powered implants. The company’s breakthrough design could broaden access to neuromodulation by making procedures less invasive and more appealing to both patients and providers.

UroMems

France-based UroMems is pioneering the first automated artificial urinary sphincter, UroActive™, for patients with stress urinary incontinence (SUI). The implant uses smart, electronic control to deliver personalized support, potentially overcoming limitations of existing mechanical sphincters. With early feasibility data showing promise, UroMems is positioning itself at the forefront of next-generation implantable devices in urology.

Andromeda Surgical

Andromeda Surgical is developing AI-driven robotic systems for laser prostate enucleation procedures such as HoLEP. By reducing the technical learning curve through automation and real-time surgical guidance, Andromeda aims to make complex prostate surgeries more accessible worldwide. Its inclusion in the AUA Innovation Nexus 2025 showcase signals strong industry interest in its autonomous robotics platform.

Illumicell (and other AI-guided imaging innovators)

Illumicell is part of a growing wave of companies focused on real-time imaging and AI-assisted visualization for urologic oncology. These technologies improve detection of bladder and prostate cancers during procedures, helping surgeons achieve cleaner margins and reduce recurrence rates. With strong interest from both clinicians and investors, this category is quickly becoming a critical segment of emerging urology innovation.

Teleflex Incorporated

Teleflex is a global leader in single-use urology devices, including catheters, drainage systems, and access solutions. Its Rüsch® portfolio is widely used in hospitals and clinics, ensuring consistent quality and reliability in urinary care. Teleflex continues to expand its product offerings with a focus on patient safety and infection prevention.

Cook Medical Inc.

Cook Medical has a long-standing presence in urology, offering minimally invasive solutions for stone management, stents, and endourology procedures. The company is known for its innovation in ureteral access and laser lithotripsy devices, backed by collaborations with clinicians to improve procedural efficiency.

KARL STORZ SE & Co. KG

Germany-based KARL STORZ is a pioneer in endoscopy and visualization technologies. In urology, it provides high-performance cystoscopes, ureteroscopes, and imaging platforms that enhance precision in diagnostics and surgery. Its continuous investments in optics and digital integration keep it at the forefront of surgical visualization.

Stryker Corporation

Stryker is a strong player in surgical urology, particularly with its advanced endoscopic visualization systems and stone management devices. Its acquisitions and R&D investments have strengthened its minimally invasive solutions, making it a partner of choice for hospitals aiming to modernize their operating rooms.

Conclusion

The urology devices market in 2025 is being reshaped by both nimble innovators and established medtech giants. Emerging companies such as Zenflow, Promaxo, Neuspera, UroMems, Andromeda Surgical, and Illumicell are driving breakthroughs with minimally invasive implants, robotics, and AI-driven diagnostics. Meanwhile, global leaders like Boston Scientific, Medtronic, Coloplast, Teleflex, and KARL STORZ continue to dominate with extensive portfolios and global reach. Together, these players are accelerating the transition toward safer, more effective, and patient-friendly urological treatments, setting the stage for the next decade of innovation in urinary care.

Anushka Gore  

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the medical devices & consumables industry. She has dedicated herself unraveling the intricate market trends and consumer behavio…